Highly sensitive real-time PCR for the detection of EGFR mutations in lung adenocarcinoma. Is it worth it?

Rodon Natalia1, Roman Ruth1, Verdu Montse1,3, Garcia Beatriz1, Pujol Merce1 and Puig Xavier 1,2,3.

1BIOPAT.Biopatologia Molecular, SL, Grup Assistencia, Barcelona, Spain; 2Hospital de Barcelona, SCIAS, Grup Assistencia, Barcelona, Spain; 3Histopat Laboratoris, Barcelona, Spain.

Background: Mutations involving the epidermal growth factor receptor (EGFR) correlate with responsiveness to tyrosine kinase inhibitors (TKIs), which significantly improves patient survival in lung adenocarcinoma (AC). These mutations are described to be more frequent in non-mucinous lepidic adenocarcinomas (nmBAC). The unquestionable importance of determining the presence of these mutations, even in samples with […]

2012-03-14T23:08:26+00:00

Genetic alterations of the epidermal growth factor receptor pathway in a series of non-small cell lung cancer characterized by morphology and immunophenotype

Verdú M,1 Colomer A,1 Erill N,1 Roman R,2 Górriz M, 1,2 Ibáñez R,1 Cordon-Cardo C,1 Puig X.1,2

1HISTOPAT Laboratoris, Barcelona, Catalonia, Spain & 2BIOPAT. Biopatologia Molecular, Grup Assistència.

Background: Non-small cell lung cancer (NSCLC) is classified in two main categories: adenocarcinoma (AC), which includes bronchioloalveolar carcinoma (BAC), and squamous cell carcinoma (SCC). Activating mutations and increased copy number of the EGFR gene have been reported in tumors from patients with NSCLC with increased response rate to tyrosine kinase inhibitors (TKIs). There is […]

2006-09-23T17:54:01+00:00

Epidermal growth factor receptor in non small cell lung cancer: Gene copy number and mutational study

Colomer A, Erill N, Verdú M, Román R, Górriz M, Ibáñez R, Menoyo A, Cordon-Cardo C, Puig X.

BIOPAT, Grup Assistència, HISTOPAT Laboratoris, Barcelona, Spain; and Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York, United States.

Background: Activating mutations of the EGFR gene were identified in tumors from patients with non small cell lung cancer (NSCLC) that responded to therapy with tyrosine kinase inhibitors (TKIs). More recently, survival has been reported to significantly increase amongst patients carrying a […]

2006-02-23T17:52:21+00:00

Carcinoma de pulmón de células no pequeñas: caracterización inmunohistoquímica y estudio molecular del gen del receptor de EGF

N Erill1, A Colomer1, M Verdú2, R Román1, A Menoyo1, Carlos Cordón-Cardó1,2,3, Xavier Puig1,2.

1 BIOPAT. Biopatologia Molecular.  Grup Assistència. Barcelona. 2 Histopat laboratoris, Barcelona. 3 Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York. 

Texto completo

Póster presentado en:

XXII Congreso de la Sociedad Española de Anatomía Patológica 2005

2005-09-01T01:25:02+00:00

Diagnostic sub-classification of non-small cell lung cancer: Importance in clinical therapeutics and prognostication

M. J. Donovan, A. Kotsianti, A. Colomer, M. Verdú, M. Clayton, H. Pang, S. Hamann, C. Cordón-Cardó, X. Puig.

Background: The association of EGFR mutations with bronchoalveolar carcinoma (BAC) / non-small cell lung cancer (NSCLC) and the therapeutic and prognostic variability reported for lung cancer has reinforced the need for more accurate NSCLC sub-classification. The present study utilizes clinical data, immunohistochemistry (IHC), molecular analyses, and quantified immunofluorescent multiplexing (QIFM) to develop a systems pathology model for NSCLC. Methods: 73 NSCLC cases; […]

2005-02-09T22:15:16+00:00